AstraZeneca PLC ADR AZN

By Rajiv Tarigopula : Johnson & Johnson ( JNJ ) , one of the world's leaders in the pharmaceutical, medical devices, and general consumer products industries, is a supreme opportunity for long-term value investors. Trading near $63 today, Johnson & Johnson has a very healthy dividend yield of over

By Kevin CC : On May 22, 2012, management at Chelsea Therapeutics ( CHTP ) held a conference call to inform investors about the results of the End-of-Review meeting the company had with the U.S. Food and Drug Administration (FDA). In March the FDA issued CHTP a complete response letter (CRL) ...

By Markus Aarnio : Navidea Biopharmaceuticals ( NAVB ), a leader in precision diagnostics, is a biopharmaceutical company developing novel radiopharmaceutical imaging agents to help identify the presence and status of disease and enable better diagnostic accuracy, clinical decision-making and ...

By Stephen Simpson : "Pay no attention to the man behind the curtain!" L. Frank Baum, The Wonderful Wizard Of Oz For a company that owes about 45% of its post-March 28 market cap to buyout rumors, biopharma Amylin Pharmaceuticals ( AMLN ) continues to be stubbornly silent on the question of whether

BRUSSELS, May 15 (Reuters) - AstraZeneca misled patent regulators more than a decade ago in a bid to block competition to its ulcer drug Losec, an adviser to Europe's top court said on Tuesday, backing a 52.5 million euro EU antitrust fine for the British drugmaker.

Wall Street Breakfast Editors submit: Top Stories German recovery helps eurozone avoid recession. German GDP rebounded in Q1 to rise 0.5% on quarter, more than double forecasts of +0.2%, boosted by exports to emerging markets. France showed zero growth and Italy experienced a worse-than-expected ...